Page last updated: 2024-12-07
convicine
Description
Convicine is a naturally occurring pyrimidine glycoside found in fava beans (Vicia faba). It is a potent inhibitor of the enzyme glucose-6-phosphate dehydrogenase (G6PD), which is responsible for the first step in the pentose phosphate pathway. This pathway is important for the production of NADPH, a reducing agent that protects cells from oxidative damage. Individuals with G6PD deficiency are unable to efficiently produce NADPH and are therefore susceptible to hemolytic anemia upon exposure to oxidative stressors, such as fava beans. Convicine is thought to be responsible for favism, a condition characterized by hemolytic anemia, jaundice, and other symptoms that can occur in individuals with G6PD deficiency who consume fava beans. Convicine has also been shown to exhibit antitumor activity in vitro. Its synthesis involves the condensation of cytosine and D-glucose. The study of convicine is important for understanding the pathogenesis of favism and for exploring its potential therapeutic applications.'
convicine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 88000 |
CHEBI ID | 3867 |
SCHEMBL ID | 4630048 |
MeSH ID | M0050095 |
Synonyms (21)
Synonym |
convicine |
C08430 |
19286-37-4 |
6-amino-5-(b-d-glucopyranosyloxy)-2,4(1h,3h)-pyrimidinedione |
AC1L3ETZ , |
6-amino-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1h-pyrimidine-2,4-dione |
AC1Q6LTN , |
unii-6o6r2591x5 |
6o6r2591x5 , |
convicine [mi] |
SCHEMBL4630048 |
CHEBI:3867 |
6-amino-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-1h-pyrimidine-2,4-dione |
surecn4630048 |
6-amino-2-hydroxy-5-(beta-d-glucopyranosyloxy)-4-pyrimidinone |
DTXSID60940958 |
4-amino-2,6-dihydroxypyrimidin-5-yl hexopyranoside |
Q27106221 |
CS-0113903 |
HY-135738 |
6-amino-5-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)pyrimidine-2,4(1h,3h)-dione |
Research Excerpts
Bioavailability
Drug Classes (1)
Class | Description |
glycoside | A glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (22)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 7 (31.82) | 18.7374 |
1990's | 6 (27.27) | 18.2507 |
2000's | 1 (4.55) | 29.6817 |
2010's | 6 (27.27) | 24.3611 |
2020's | 2 (9.09) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 33.01
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 33.01 (24.57) | Research Supply Index | 3.22 (2.92) | Research Growth Index | 5.39 (4.65) | Search Engine Demand Index | 41.67 (26.88) | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 24 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |